GLP-1 analogues have contributed significantly to the treatment of T2DM, as these therapies result in better glycemic control through a variety of mechanisms. GLP-1 may also be an interesting target for NAFLD and NASH therapies.
It has been demonstrated that the long-acting GLP-1 analogue Liraglutide decreases hepatic de novo lipogenesis in patients with NASH.1 Furthermore, Liraglutide significantly improves liver enzyme concentrations, hepatocyte ballooning, and histological steatosis, while also preventing progression of fibrosis.2
Liraglutide does not interfere in the Mercodia Total GLP-1 NL-ELISA which means that the ELISA assay is suitable for GLP-1 measurements even in samples from patients undergoing analogue treatment.
HEADQUARTERS IN UPPSALA, SWEDEN:
SYLVENIUSGATAN 8A
SE-754 50 UPPSALA, SWEDEN
© COPYRIGHT 2017
EMAIL US
PHONE + 46 18 57 00 70
FAX + 46 18 57 00 80
Visit us on social media:
facebook.com/mercodia twitter.com/Mercodia linkedin.com/company/mercodia-ab plus.google.com/113076055858025990989
